[1]	Li C, Wu X, Feng X, et al. A novel conditioning regimen improves outcomes in β-thalassemia major patients using unrelated donor peripheral blood stem cell transplantation[J]. Blood, 2012, 120(19): 3875-3881. DOI: 10.1182/blood-2012-03-417998 . https://www.ncbi.nlm.nih.gov/pubmed/22968457 本文引用 [3]

[2]	He Y, Jiang H, Li C, et al. Long-term results of the NF-08-TM protocol in stem cell transplant for patients with thalassemia major: a multi-center large-sample study[J]. Am J Hematol, 2020, 95(11): E297-E299. DOI: 10.1002/ajh.25969 . https://www.ncbi.nlm.nih.gov/pubmed/32818293 本文引用 [1]

[3]	Liu R, Xiao H, Qin C, et al. A multi-center clinical trial of allogeneic hematopoietic stem cell transplants in transfusion dependent thalassemia[J]. Blood, 2024, 144(): 378. DOI: 10.1182/blood-2024-204984 . 本文引用 [5] 摘要 Suppl 1

[4]	Gordon HG, Andrew DO, Gunn EV, et al. GRADE: 证据质量和推荐强度分级的共识[J]. 中国循证医学杂志, 2009, 9(1): 8-11. DOI: 10.3969/j.issn.1672-2531.2009.01.005 . 本文引用 [2]

[5]

Greco R, Ruggeri A, McLornan DP, et al. Indications for haematopoietic cell transplantation and CAR-T for haematological diseases, solid tumours and immune disorders: 2025 EBMT practice recommendations[J]. Bone Marrow Transplant, 20250(11): 1499-1525. PMCID: PMC12583170. DOI: 10.1038/s41409-025-02701-3 . https://www.ncbi.nlm.nih.gov/pubmed/40926035 本文引用 [1]

[6]

Ahmed S, Soliman A, De Sanctis V, et al. A short review on growth and endocrine long-term complications in children and adolescents with β-thalassemia major: conventional treatment versus hematopoietic stem cell transplantation[J]. Acta Biomed, 2022, 93(4): e2022290. PMCID: PMC9534255. DOI: 10.23750/abm.v93i4.13331 . https://www.ncbi.nlm.nih.gov/pubmed/36043958 本文引用 [1]

[7]

Baronciani D, Boumendil A, Dalissier A, et al. Hematopoietic cell transplantation in thalassemia and sickle cell disease: report from the European Society for Blood and Bone Marrow Transplantation Hemoglobinopathy Registry: 2000-2017[J]. Blood, 2018, 132(): 168. DOI: 10.1182/blood-2018-168 . 本文引用 [2] 摘要 Suppl 1

[8]	Li C, Mathews V, Kim S, et al. Related and unrelated donor transplantation for β-thalassemia major: results of an international survey[J]. Blood Adv, 2019, 3(17): 2562-2570. PMCID: PMC6737407. DOI: 10.1182/bloodadvances.2019000291 . https://www.ncbi.nlm.nih.gov/pubmed/31471325 本文引用 [4]

[9]	Liang X, Yang G, Shi L, et al. Serum ferritin is a risk factor for pulmonary dysfunction in young patients with transfusion-dependent thalassemia[J]. Heliyon, 2024, 10(19): e38069. PMCID: PMC11471533. DOI: 10.1016/j.heliyon.2024.e38069 . https://www.ncbi.nlm.nih.gov/pubmed/39403455 本文引用 [1]

[10]	Chen L, He Y, Wen J, et al. MRI evaluation of liver and cardiac iron overload impact on hematopoietic stem cell transplantation with β-thalassemia major[J]. Blood, 2019, 134(): 5738. DOI: 10.1182/blood-2019-128903 . 本文引用 [1] 摘要 Suppl 1

[11]	中华医学会医学遗传学分会遗传病临床实践指南撰写组. β-地中海贫血的临床实践指南[J]. 中华医学遗传学杂志, 2020, 37(3): 243-251. DOI: 10.3760/cma.j.issn.1003-9406.2020.03.004 . https://www.ncbi.nlm.nih.gov/pubmed/32128739 本文引用 [1]

[12]

Sanpakit K, Narkbunnam N, Buaboonnam J, et al. Impact of splenectomy on outcomes of hematopoietic stem cell transplantation in pediatric patients with transfusion-dependent thalassemia[J]. Pediatr Blood Cancer, 2020, 67(9): e28483. DOI: 10.1002/pbc.28483 . https://www.ncbi.nlm.nih.gov/pubmed/32568454 本文引用 [1]

[13]	He Y, Wu X, Ruan Y, et al. Hematopoietic stem cell transplantation for patients with β-thalassemia major underwent pre-transplant splenectomy[J]. Blood, 2014, 124(21): 5932. DOI: 10.1182/blood.V124.21.5932.5932 . 本文引用 [1]

[14]

Li Q, Luo J, Zhang Z, et al. G-CSF-Mobilized blood and bone marrow grafts as the source of stem cells for HLA-identical sibling transplantation in patients with thalassemia major[J]. Biol Blood Marrow Transplant, 2019, 25(10): 2040-2044. DOI: 10.1016/j.bbmt.2019.06.009 . https://www.ncbi.nlm.nih.gov/pubmed/31207293 本文引用 [2]

[15]	温建芸, 陈丽白, 何岳林, 等. 人类白细胞抗原相合同胞新鲜脐血移植治疗儿童β重型地中海贫血[J]. 中国组织工程研究, 2025, 29(23): 4899-4906. DOI: 10.12307/2025.095 . 本文引用 [1]

[16]	Locatelli F, Kabbara N, Ruggeri A, et al. Outcome of patients with hemoglobinopathies given either cord blood or bone marrow transplantation from an HLA-identical sibling[J]. Blood, 2013, 122(6): 1072-1078. DOI: 10.1182/blood-2013-03-489112 . https://www.ncbi.nlm.nih.gov/pubmed/23692854 本文引用 [1]

[17]

Ghavamzadeh A, Kasaeian A, Rostami T, et al. Comparable outcomes of allogeneic peripheral blood versus bone marrow hematopoietic stem cell transplantation in major thalassemia: a multivariate long-term cohort analysis[J]. Biol Blood Marrow Transplant, 2019, 25(2): 307-312. DOI: 10.1016/j.bbmt.2018.09.026 . https://www.ncbi.nlm.nih.gov/pubmed/30266673 本文引用 [1]

[18]	Petersdorf EW, Bengtsson M, De Santis D, et al. Role of HLA-DP expression in graft-versus-host disease after unrelated donor transplantation[J]. J Clin Oncol, 2020, 38(24): 2712-2718. PMCID: PMC7430213. DOI: 10.1200/jco.20.00265 . https://www.ncbi.nlm.nih.gov/pubmed/32479188 本文引用 [1]

[19]

Xiao H, Huang Q, Lai Y, et al. Haploidentical hematopoietic stem cell transplantation in pediatric transfusion-dependent thalassemia: a systematic review and meta-analysis[J]. Transplant Cell Ther, 2025, 31(2): 101.e1-101.e12. DOI: 10.1016/j.jtct.2024.12.001 . https://www.ncbi.nlm.nih.gov/pubmed/39647520 本文引用 [1]

[20]

Jin X, Yang Y, Chen X. Post-transplant cyclophosphamide versus anti-thymocyte globulin in haploidentical stem cell transplantation: a systematic review and meta-analysis[J]. Ann Hematol, 2025, 104(3): 1317-1328. PMCID: PMC12031761. DOI: 10.1007/s00277-025-06199-z . https://www.ncbi.nlm.nih.gov/pubmed/39847115 本文引用 [1]

[21]

Wang X, Zhang X, Yu U, et al. Co-transplantation of haploidentical stem cells and a dose of unrelated cord blood in pediatric patients with thalassemia major[J]. Cell Transplant, 2021, 30: 963689721994808. PMCID: PMC7894585. DOI: 10.1177/0963689721994808 . https://www.ncbi.nlm.nih.gov/pubmed/33593080 本文引用 [1]

[22]	Liao J, Bu C, He L, et al. A novel protocol improves engraftment in Tαβ+ cell depleted haplo-HSCT for patients with thalassemia major[J]. Blood, 2023, 142(): 4953. DOI: 10.1182/blood-2023-185575 . 本文引用 [2] 摘要 Suppl 1

[23]

Ciurea SO, Cao K, Fernandez-Vina M, et al. The European Society for Blood and Marrow Transplantation (EBMT) consensus guidelines for the detection and treatment of donor-specific anti-HLA antibodies (DSA) in haploidentical hematopoietic cell transplantation[J]. Bone Marrow Transplant, 2018, 53(5): 521-534. PMCID: PMC7232774. DOI: 10.1038/s41409-017-0062-8 . https://www.ncbi.nlm.nih.gov/pubmed/29335625 本文引用 [1]

[24]	Pilo F, Angelucci E. Iron toxicity and hemopoietic cell transplantation: time to change the paradigm[J]. Mediterr J Hematol Infect Dis, 2019, 11(1): e2019030. PMCID: PMC6548208. DOI: 10.4084/mjhid.2019.030 . https://www.ncbi.nlm.nih.gov/pubmed/31205634 本文引用 [1]

[25]	Sodani P, Gaziev D, Polchi P, et al. New approach for bone marrow transplantation in patients with class 3 thalassemia aged younger than 17 years[J]. Blood, 2004, 104(4): 1201-1203. DOI: 10.1182/blood-2003-08-2800 . https://www.ncbi.nlm.nih.gov/pubmed/15039283 本文引用 [1]

[26]	Lucarelli G, Isgrò A, Sodani P, et al. Hematopoietic stem cell transplantation in thalassemia and sickle cell anemia[J]. Cold Spring Harb Perspect Med, 2012, 2(5): a011825. PMCID: PMC3331690. DOI: 10.1101/cshperspect.a011825 . https://www.ncbi.nlm.nih.gov/pubmed/22553502

[27]

Dovern E, Aydin M, Hazenberg MD, et al. Azathioprine/hydroxyurea preconditioning prior to nonmyeloablative matched sibling donor hematopoietic stem cell transplantation in adults with sickle cell disease: a prospective observational cohort study[J]. Am J Hematol, 2024, 99(8): 1523-1531. DOI: 10.1002/ajh.27360 . https://www.ncbi.nlm.nih.gov/pubmed/38733340 本文引用 [1]

[28]

Yang H, Li X, Que L, et al. A novel conditioning regimen with pre-transplantation immunosuppression reduces the complication rates in hematopoietic stem cell transplantation in transfusion-dependent β-thalassemia[J]. Stem Cell Res Ther, 2024, 15(1): 495. PMCID: PMC11663346. DOI: 10.1186/s13287-024-04103-6 . https://www.ncbi.nlm.nih.gov/pubmed/39709479 本文引用 [1]

[29]

Anurathapan U, Pakakasama S, Mekjaruskul P, et al. Outcomes of thalassemia patients undergoing hematopoietic stem cell transplantation by using a standard myeloablative versus a novel reduced-toxicity conditioning regimen according to a new risk stratification[J]. Biol Blood Marrow Transplant, 2014, 20(12): 2066-2071. PMCID: PMC5538782. DOI: 10.1016/j.bbmt.2014.07.016 . https://www.ncbi.nlm.nih.gov/pubmed/25064743

[30]

Anurathapan U, Hongeng S, Pakakasama S, et al. Hematopoietic stem cell transplantation for severe thalassemia patients from haploidentical donors using a novel conditioning regimen[J]. Biol Blood Marrow Transplant, 2020, 26(6): 1106-1112. DOI: 10.1016/j.bbmt.2020.01.002 . https://www.ncbi.nlm.nih.gov/pubmed/31931116 本文引用 [1]

[31]

Lai YR, Chen YH, Hu DM, et al. Multicenter phase II study of a combination of cyclosporine A, methotrexate and mycophenolate mofetil for GVHD prophylaxis: results of the Chinese Bone Marrow Transplant Cooperative Group (CBMTCG)[J]. J Hematol Oncol, 2014, 7: 59. PMCID: PMC4237802. DOI: 10.1186/s13045-014-0059-3 . https://www.ncbi.nlm.nih.gov/pubmed/25139202 本文引用 [1]

[32]

Brissot E, Labopin M, Moiseev I, et al. Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10/10 HLA-matched unrelated donors[J]. J Hematol Oncol, 2020, 13(1): 87. PMCID: PMC7333262. DOI: 10.1186/s13045-020-00923-0 . https://www.ncbi.nlm.nih.gov/pubmed/32620146 本文引用 [1]

[33]

Gong S, Tian X, Yang R, et al. Uniform graft-versus-host disease prophylaxis using post-transplantation cyclophosphamide, methotrexate, and cyclosporine following peripheral blood hematopoietic stem cell transplantation from matched and haploidentical donors for transfusion-dependent thalassemia: a retrospective report from the Bone Marrow Failure Working Group of Hunan Province, China[J]. Transplant Cell Ther, 2024, 30(12): 1213.e1-1213.e12. DOI: 10.1016/j.jtct.2024.08.022 . https://www.ncbi.nlm.nih.gov/pubmed/39236789 本文引用 [1]

[34]

Ruggeri A, Labopin M, Bacigalupo A, et al. Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with acute leukemia, on behalf of ALWP-EBMT[J]. J Hematol Oncol, 2018, 11(1): 40. PMCID: PMC5855999. DOI: 10.1186/s13045-018-0586-4 . https://www.ncbi.nlm.nih.gov/pubmed/29544522 本文引用 [1]

[35]

Penack O, Marchetti M, Aljurf M, et al. Prophylaxis and management of graft-versus-host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation[J]. Lancet Haematol, 2024, 11(2): e147-e159. DOI: 10.1016/S2352-3026(23)00342-3 . https://www.ncbi.nlm.nih.gov/pubmed/38184001 本文引用 [1]

[36]

Ruggeri A, Sun Y, Labopin M, et al. Post-transplant cyclophosphamide versus anti-thymocyte globulin as graft- versus-host disease prophylaxis in haploidentical transplant[J]. Haematologica, 2017, 102(2): 401-410. PMCID: PMC5286948. DOI: 10.3324/haematol.2016.151779 . https://www.ncbi.nlm.nih.gov/pubmed/27758821 本文引用 [1]

[37]

Lisini D, Zecca M, Giorgiani G, et al. Donor/recipient mixed chimerism does not predict graft failure in children with beta-thalassemia given an allogeneic cord blood transplant from an HLA-identical sibling[J]. Haematologica, 2008, 93(12): 1859-1867. DOI: 10.3324/haematol.13248 . https://www.ncbi.nlm.nih.gov/pubmed/18945748 本文引用 [1]

[38]	Tan W, He Y, Feng X, et al. Mixed chimerism after allogeneic hematopoietic stem cell transplantation in patients with β thalassemia: impact on outcome and risk factors[J]. Blood, 2020, 136 (): 48-49. DOI: 10.1182/blood-2020-134448 . 本文引用 [1] 摘要 Suppl 1

[39]

Chen H, Li XY, Zhan LP, et al. Prediction, management, and prognosis of mixed chimerism after hematopoietic stem cell transplantation in transfusion-dependent pediatric thalassemia patients[J]. Pediatr Transplant, 2020, 24(8): e13876. DOI: 10.1111/petr.13876 . https://www.ncbi.nlm.nih.gov/pubmed/33098346 本文引用 [1]

[40]

Dholaria B, Savani BN, Labopin M, et al. Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT[J]. Haematologica, 2020, 105(1): 47-58. PMCID: PMC6939532. DOI: 10.3324/haematol.2019.219790 . https://www.ncbi.nlm.nih.gov/pubmed/31537691 本文引用 [1]

[41]	Liao J, Liang S, Chen J, et al. Treatment of mixed chimerism after hematopoietic stem cell transplantation in patients with thalassemia major[J]. Am J Pediatr, 2024, 10(1): 18-25. DOI: 10.11648/j.ajp.20241001.14 . 本文引用 [1]

[42]	Lucarelli G, Angelucci E, Giardini C, et al. Fate of iron stores in thalassaemia after bone-marrow transplantation[J]. Lancet, 1993, 342(8884): 1388-1391. DOI: 10.1016/0140-6736(93)92753-g . https://www.ncbi.nlm.nih.gov/pubmed/7901682 本文引用 [1]

[43]

Angelucci E, Muretto P, Lucarelli G, et al. Phlebotomy to reduce iron overload in patients cured of thalassemia by bone marrow transplantation. Italian Cooperative Group for Phlebotomy Treatment of Transplanted Thalassemia Patients[J]. Blood, 1997, 90(3): 994-998. https://www.ncbi.nlm.nih.gov/pubmed/9242528 本文引用 [1]

[44]

Inati A, Kahale M, Sbeiti N, et al. One-year results from a prospective randomized trial comparing phlebotomy with deferasirox for the treatment of iron overload in pediatric patients with thalassemia major following curative stem cell transplantation[J]. Pediatr Blood Cancer, 2017, 64(1): 188-196. DOI: 10.1002/pbc.26213 . https://www.ncbi.nlm.nih.gov/pubmed/27576370 本文引用 [1]

[45]

Kupesiz FT, Sivrice C, Akinel A, et al. Efficacy and safety of iron chelation therapy after allogeneic hematopoietic stem cell transplantation in pediatric thalassemia patients: a retrospective observational study[J]. J Pediatr Hematol Oncol, 2022, 44(1): e26-e34. DOI: 10.1097/mph.0000000000002328 . https://www.ncbi.nlm.nih.gov/pubmed/34986131 本文引用 [1]

[46]

Pan T, Ji Y, Liu H, et al. Impact of iron overload and iron chelation with deferasirox on outcomes of patients with severe aplastic anemia after allogeneic hematopoietic stem cell transplantation[J]. Transplant Cell Ther, 2023, 29(8): 507.e1-507.e8. DOI: 10.1016/j.jtct.2023.04.016 . https://www.ncbi.nlm.nih.gov/pubmed/37116582 本文引用 [1]

[47]

Corbacioglu S, Carreras E, Ansari M, et al. Diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in pediatric patients: a new classification from the European society for blood and marrow transplantation[J]. Bone Marrow Transplant, 2018, 53(2): 138-145. PMCID: PMC5803572. DOI: 10.1038/bmt.2017.161 . https://www.ncbi.nlm.nih.gov/pubmed/28759025 本文引用 [2]

[48]

Cheuk DK, Chiang AK, Ha SY, et al. Interventions for prophylaxis of hepatic veno-occlusive disease in people undergoing haematopoietic stem cell transplantation[J]. Cochrane Database Syst Rev, 2015, 2015(5): CD009311. PMCID: PMC10891422. DOI: 10.1002/14651858.CD009311.pub2 . https://www.ncbi.nlm.nih.gov/pubmed/26017019 本文引用 [1]

[49]

Sola M, Bhatt V, Palazzo M, et al. Low-dose unfractionated heparin prophylaxis is a safe strategy for the prevention of hepatic sinusoidal obstruction syndrome after myeloablative adult allogenic stem cell transplant[J]. Bone Marrow Transplant, 2022, 57(7): 1095-1100. PMCID: PMC9271583. DOI: 10.1038/s41409-022-01689-4 . https://www.ncbi.nlm.nih.gov/pubmed/35477992 本文引用 [1]

[50]

Stutz L, Halter JP, Heim D, et al. Low incidence of hepatic sinusoidal obstruction syndrome/veno-occlusive disease in adults undergoing allogenic stem cell transplantation with prophylactic ursodiol and low-dose heparin[J]. Bone Marrow Transplant, 2022, 57(3): 391-398. PMCID: PMC8907064. DOI: 10.1038/s41409-021-01546-w . https://www.ncbi.nlm.nih.gov/pubmed/34980902 本文引用 [1]

[51]

Corbacioglu S, Topaloglu O, Aggarwal S. A systematic review and meta-analysis of studies of defibrotide prophylaxis for veno-occlusive disease/sinusoidal obstruction syndrome[J]. Clin Drug Investig, 2022, 42(6): 465-476. PMCID: PMC9188533. DOI: 10.1007/s40261-022-01140-y . https://www.ncbi.nlm.nih.gov/pubmed/35594010 本文引用 [1]

[52]	Senzolo M, Germani G, Cholongitas E, et al. Veno occlusive disease: update on clinical management[J]. World J Gastroenterol, 2007, 13(29): 3918-3924. PMCID: PMC4171162. DOI: 10.3748/wjg.v13.i29.3918 . https://www.ncbi.nlm.nih.gov/pubmed/17663504 本文引用 [1]

[53]

Bradford J, Marshall K, Stanek J, et al. High tacrolimus trough concentrations is an early predictor of hepatic veno-occlusive disease/sinusoidal obstruction syndrome after allogeneic hematopoietic cell transplantation in children[J]. Transplant Cell Ther, 2024, 30(2): S451-S452. DOI: 10.1016/j.jtct.2023.12.654 . 本文引用 [1]

[54]	Richardson PG, Riches ML, Kernan NA, et al. Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure[J]. Blood, 2016, 127(13): 1656-1665. PMCID: PMC4817309. DOI: 10.1182/blood-2015-10-676924 . https://www.ncbi.nlm.nih.gov/pubmed/26825712 本文引用 [1]

[55]

Kernan NA, Grupp S, Smith AR, et al. Final results from a defibrotide treatment-IND study for patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome[J]. Br J Haematol, 2018, 181(6): 816-827. PMCID: PMC6032999. DOI: 10.1111/bjh.15267 . https://www.ncbi.nlm.nih.gov/pubmed/29767845 本文引用 [1]

[56]

Corbacioglu S, Greil J, Peters C, et al. Defibrotide in the treatment of children with veno-occlusive disease (VOD): a retrospective multicentre study demonstrates therapeutic efficacy upon early intervention[J]. Bone Marrow Transplant, 2004, 33(2): 189-195. DOI: 10.1038/sj.bmt.1704329 . https://www.ncbi.nlm.nih.gov/pubmed/14661036 本文引用 [1]

[57]

Al Beihany A, Al Omar H, Sahovic E, et al. Successful treatment of hepatic veno-occlusive disease after myeloablative allogeneic hematopoietic stem cell transplantation by early administration of a short course of methylprednisolone[J]. Bone Marrow Transplant, 2008, 41(3): 287-291. DOI: 10.1038/sj.bmt.1705896 . https://www.ncbi.nlm.nih.gov/pubmed/17982501 本文引用 [1]

[58]

Myers KC, Lawrence J, Marsh RA, et al. High-dose methylprednisolone for veno-occlusive disease of the liver in pediatric hematopoietic stem cell transplantation recipients[J]. Biol Blood Marrow Transplant, 2013, 19(3): 500-503. PMCID: PMC5684704. DOI: 10.1016/j.bbmt.2012.11.011 . https://www.ncbi.nlm.nih.gov/pubmed/23211838 本文引用 [1]

[59]	Sockel K, Neu A, Goeckenjan M, et al. Hope for motherhood: pregnancy after allogeneic hematopoietic cell transplantation (a national multicenter study)[J]. Blood, 2024, 144(14): 1532-1542. DOI: 10.1182/blood.2024024342 . https://www.ncbi.nlm.nih.gov/pubmed/39007722 本文引用 [1]

[60]	Ruan X, Cheng J, Korell M, et al. Ovarian tissue cryopreservation and transplantation prevents iatrogenic premature ovarian insufficiency: first 10 cases in China[J]. Climacteric, 2020, 23(6): 574-580. DOI: 10.1080/13697137.2020.1767569 . https://www.ncbi.nlm.nih.gov/pubmed/32508143 本文引用 [1]

[61]	李晶洁, 方丛, 李满超, 等. 造血干细胞移植术后的重度β地中海贫血患者自体移植冻融卵巢组织诱导青春期发育成功病例1例并文献复习[J]. 中华生殖与避孕杂志, 2022, 42(11): 1187-1191. DOI: 10.3760/cma.j.cn101441-20220730-00318 .

[62]	Demeestere I, Simon P, Dedeken L, et al. Live birth after autograft of ovarian tissue cryopreserved during childhood[J]. Hum Reprod, 2015, 30(9): 2107-2109. DOI: 10.1093/humrep/dev128 . https://www.ncbi.nlm.nih.gov/pubmed/26062556 本文引用 [1]

[63]

Rahal I, Galambrun C, Bertrand Y, et al. Late effects after hematopoietic stem cell transplantation for β-thalassemia major: the French national experience[J]. Haematologica, 2018, 103(7): 1143-1149. PMCID: PMC6029533. DOI: 10.3324/haematol.2017.183467 . https://www.ncbi.nlm.nih.gov/pubmed/29599204 本文引用 [1]

[64]

Shenoy S, Gaziev J, Angelucci E, et al. Late effects screening guidelines after hematopoietic cell transplantation (HCT) for hemoglobinopathy: consensus statement from the second Pediatric Blood and Marrow Transplant Consortium international conference on late effects after pediatric HCT[J]. Biol Blood Marrow Transplant, 2018, 24(7): 1313-1321. DOI: 10.1016/j.bbmt.2018.04.002 . https://www.ncbi.nlm.nih.gov/pubmed/29653206 本文引用 [2]

[65]

Kuhlen M, Kunstreich M, Niinimäki R, et al. Guidance to bone morbidity in children and adolescents undergoing allogeneic hematopoietic stem cell transplantation[J]. Biol Blood Marrow Transplant, 2020, 26(2): e27-e37. DOI: 10.1016/j.bbmt.2019.10.007 . https://www.ncbi.nlm.nih.gov/pubmed/31618689 本文引用 [2]

[66]	Khan Z, Agarwal NB, Bhurani D, et al. Risk factors for hematopoietic stem cell transplantation-associated bone loss[J]. Transplant Cell Ther, 2021, 27(3): 212-221. DOI: 10.1016/j.bbmt.2020.10.002 . https://www.ncbi.nlm.nih.gov/pubmed/33045384 本文引用 [1]

[67]	de la Cámara R, Meisel R. Vaccinations[M]//Sureda A, Corbacioglu S, Greco R, et al. The EBMT Handbook: Hematopoietic Cell Transplantation and Cellular Therapies. Cham: Springer International Publishing, 2024: 249-264. 本文引用 [1]